The relationship between the quantitative evaluation of thyroid bed uptake and the disappearance of accumulation in adjuvant radioactive iodine therapy for differentiated thyroid cancer

被引:8
|
作者
Konishi, Kenta [1 ]
Ishiba, Ryo [1 ]
Ikenohira, Tsutomu [1 ]
Asao, Tomoyuki [1 ]
Hirata, Masanori [1 ]
Ohira, Keiichi [1 ]
Komatsu, Tetsuya [1 ]
Sawada, Michifumi [2 ]
Tanahashi, Yukichi [3 ]
Goshima, Satoshi [3 ]
Magata, Yasuhiro [4 ]
Nakamura, Katsumasa [1 ]
机构
[1] Hamamatsu Univ Sch Med, Dept Radiat Oncol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan
[2] Hamamatsu Univ Sch Med, Dept Radiol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan
[3] Hamamatsu Univ Sch Med, Dept Diagnost Radiol & Nucl Med, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan
[4] Hamamatsu Univ Sch Med, Preeminent Med Photon Educ & Res Ctr, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan
关键词
Thyroid cancer; Radioactive iodine therapy; Adjuvant therapy; Quantitative evaluation; Absolute radioactivity concentration; CARCINOMA; ABLATION;
D O I
10.1007/s12149-020-01546-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective Iodine-131 (I-131) radioactive iodine therapy (RAI) after total thyroidectomy is the standard treatment for patients with differentiated thyroid cancer (DTC). We investigated the relationship between the quantitative parameters of the iodine uptake and the disappearance of the accumulation in the thyroid bed in adjuvant therapy using a 1.11 GBq or 3.70 GBq dose of I-131. Methods We retrospectively analyzed the cases of 40 patients with DTC who were treated with RAI at our institution between April 2017 and August 2019. The patients were treated with the I-131 dose of 1.11 GBq (n = 25) or 3.70 GBq (n = 15) after total thyroidectomy. The I-131 whole-body scan and hybrid single-photon emission computed tomography/X-ray computed tomography (SPECT/CT) were performed 3 days after RAI. Using image analysis software, we measured the standardized uptake value (SUV) and absolute radioactivity concentration (kBq/ml) on the target lesions with the highest uptake in the thyroid bed. Results The median period from RAI to the evaluation of the absence of uptake of the thyroid bed was 6.75 months. After RAI, uptake of the thyroid bed disappeared in 26 of the 40 patients. The disappearance rate was significantly higher in the 3.70 GBq group than in the 1.11 GBq group (86.7% vs. 52.0%, respectively; p = 0.029). However, there were no significant differences in the values of kBq/ml or SUV between the 1.11 GBq group and 3.70 GBq group. On the other hand, the group in which the uptake disappeared after RAI showed significantly higher kBq/ml max and kBq/ml mean values than the group in which the uptake did not disappear after RAI (p = 0.028, p = 0.032, respectively). The SUVmax and SUVmean also tended to be higher in the disappeared-uptake group than the not-disappeared-uptake group, but the differences were not significant (p = 0.166, p = 0.176, respectively). Conclusions The quantitative evaluation might be useful as one of the predictive indicators of the disappearance of the accumulation of radioactive iodine in the thyroid bed.
引用
收藏
页码:159 / 166
页数:8
相关论文
共 50 条
  • [1] The relationship between the quantitative evaluation of thyroid bed uptake and the disappearance of accumulation in adjuvant radioactive iodine therapy for differentiated thyroid cancer
    Kenta Konishi
    Ryo Ishiba
    Tsutomu Ikenohira
    Tomoyuki Asao
    Masanori Hirata
    Keiichi Ohira
    Tetsuya Komatsu
    Michifumi Sawada
    Yukichi Tanahashi
    Satoshi Goshima
    Yasuhiro Magata
    Katsumasa Nakamura
    Annals of Nuclear Medicine, 2021, 35 : 159 - 166
  • [2] Association between successful adjuvant therapy and quantitative evaluation of radioactive iodine accumulation in the thyroid bed in patients with differentiated thyroid cancer
    Iizuka, Y.
    Katagiri, T.
    Nakashima, R.
    Inoue, M.
    Nakamura, K.
    Mizowaki, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S664 - S664
  • [3] Appropriate dosing of adjuvant radioactive iodine for differentiated thyroid cancer
    Bohinc, Brittany N.
    Perkins, Jennifer M.
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (01) : 31 - 35
  • [4] Radioactive iodine therapy in poorly differentiated thyroid cancer
    R Michael Tuttle
    Ravinder K Grewal
    Steve M Larson
    Nature Clinical Practice Oncology, 2007, 4 : 665 - 668
  • [5] Radioactive iodine therapy in poorly differentiated thyroid cancer
    Tuttle, R. Michael
    Grewal, Ravinder K.
    Larson, Steve M.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (11): : 665 - 668
  • [6] Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer
    Verburg, Frederik A.
    Haenscheid, Heribert
    Luster, Markus
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 31 (03) : 279 - 290
  • [7] Radioactive Iodine Therapy in Differentiated Thyroid Cancer: 2020 Update
    Ciarallo, Anthony
    Rivera, Juan
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2020, 215 (02) : 285 - 291
  • [8] The efficacy of adjuvant radioactive iodine therapy for patients with recurrent differentiated thyroid carcinoma
    Maskell, David
    Benson, Richard
    Harrison, Inge
    Barnett, Gill
    Jefferies, Sarah
    CLINICAL ONCOLOGY, 2018, 30 : E2 - E3
  • [9] Insights into the association between radioactive iodine therapy and cardiovascular disease in differentiated thyroid cancer
    Stanciu, A. E.
    Bolovan, M.
    Stanciu, M. M.
    Zamfirescu, A.
    CLINICA CHIMICA ACTA, 2024, 558
  • [10] Usefulness of quantitative hepatic accumulation for prognostic implications for radioactive iodine-refractory differentiated thyroid cancer
    Nakayama, Michihiro
    Okizaki, Atsutaka
    Takahashi, Koji
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57